Trial Profile

A Randomized, Double Blind Study of Biomarkers Predictive of Improvement in Progression Free Survival in Patients With Advanced Pancreatic Cancer Treated With Tarceva.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary)
Indications Pancreatic cancer
Focus Biomarker; Pharmacogenomic; Therapeutic Use
Acronyms MARK
Sponsors Roche

Most Recent Events

31 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
26 Jan 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2014 to 1 Dec 2015.
26 Jan 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com